Galectin Therapeutics (GALT) Tops Q1 EPS by 5c

Galectin Therapeutics (NASDAQ: GALT) reported Q1 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Lockheed Martin wins $83 million Army missile contract